EA202092002A1 - 5-гетероарилзамещенные индазол-3-карбоксамиды и их получение и применение - Google Patents
5-гетероарилзамещенные индазол-3-карбоксамиды и их получение и применениеInfo
- Publication number
- EA202092002A1 EA202092002A1 EA202092002A EA202092002A EA202092002A1 EA 202092002 A1 EA202092002 A1 EA 202092002A1 EA 202092002 A EA202092002 A EA 202092002A EA 202092002 A EA202092002 A EA 202092002A EA 202092002 A1 EA202092002 A1 EA 202092002A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- carboxamides
- preparation
- application
- heteroaryl substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634656P | 2018-02-23 | 2018-02-23 | |
| PCT/US2019/019129 WO2019165192A1 (en) | 2018-02-23 | 2019-02-22 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092002A1 true EA202092002A1 (ru) | 2021-01-21 |
Family
ID=65812386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092002A EA202092002A1 (ru) | 2018-02-23 | 2019-02-22 | 5-гетероарилзамещенные индазол-3-карбоксамиды и их получение и применение |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10934297B2 (enExample) |
| EP (1) | EP3755696B1 (enExample) |
| JP (1) | JP7369132B2 (enExample) |
| KR (1) | KR102861944B1 (enExample) |
| CN (1) | CN112020501A (enExample) |
| AU (1) | AU2019224075A1 (enExample) |
| BR (1) | BR112020017087A2 (enExample) |
| CA (1) | CA3091913A1 (enExample) |
| CL (1) | CL2020002177A1 (enExample) |
| EA (1) | EA202092002A1 (enExample) |
| ES (1) | ES2945558T3 (enExample) |
| IL (1) | IL276814A (enExample) |
| MA (1) | MA51908A (enExample) |
| MX (1) | MX2020008852A (enExample) |
| PE (1) | PE20211447A1 (enExample) |
| PH (1) | PH12020551300A1 (enExample) |
| SG (1) | SG11202008029UA (enExample) |
| WO (1) | WO2019165192A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3755696B1 (en) | 2018-02-23 | 2023-04-05 | BioSplice Therapeutics, Inc. | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
| ES2913975T3 (es) * | 2018-05-07 | 2022-06-07 | Acraf | Compuestos de 1H-indazol-3-carboxamida como inhibidores de la glucógeno sintasa cinasa-3 beta |
| JP7444458B2 (ja) * | 2018-09-21 | 2024-03-06 | 学校法人福岡大学 | プリオン病治療薬 |
| EP4079732A4 (en) * | 2019-12-16 | 2023-10-18 | Korea Research Institute of Chemical Technology | NEW INDAZOLE DERIVATIVE AND ITS USE |
| WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| WO2024259121A1 (en) * | 2023-06-14 | 2024-12-19 | Prothena Biosciences Limited | Bicyclic heteroaromatic compounds for treating neurological disorders |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
| DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
| GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| MXPA05003317A (es) | 2002-09-25 | 2005-07-05 | Memory Pharm Corp | Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos. |
| FR2845382A1 (fr) * | 2002-10-02 | 2004-04-09 | Sanofi Synthelabo | Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique |
| US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| FR2867778B1 (fr) * | 2004-03-16 | 2006-06-09 | Sanofi Synthelabo | Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme |
| EP1735306A2 (en) | 2004-03-25 | 2006-12-27 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| CN101001856A (zh) * | 2004-03-25 | 2007-07-18 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途 |
| WO2011050245A1 (en) * | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| KR20140047160A (ko) * | 2011-08-12 | 2014-04-21 | 에프. 호프만-라 로슈 아게 | 인다졸 화합물, 조성물 및 사용 방법 |
| IN2014CN02646A (enExample) * | 2011-09-14 | 2015-08-07 | Samumed Llc | |
| AU2013224302B2 (en) | 2012-02-21 | 2017-03-30 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| CN106535890A (zh) | 2014-03-20 | 2017-03-22 | 萨穆梅德有限公司 | 5‑取代的吲唑‑3‑羧酰胺及其制备和应用 |
| WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
| MX380092B (es) | 2015-11-06 | 2025-03-11 | Samumed Llc | Tratamiento de la osteoartritis. |
| MX390577B (es) | 2016-06-01 | 2025-03-20 | Samumed Llc | Proceso de preparación de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida. |
| JP2019535672A (ja) | 2016-10-21 | 2019-12-12 | サミュメッド リミテッド ライアビリティ カンパニー | インダゾール−３−カルボキサミドの使用方法およびｗｎｔ／β−カテニンシグナル伝達経路阻害剤としてのそれらの使用 |
| EP3755696B1 (en) | 2018-02-23 | 2023-04-05 | BioSplice Therapeutics, Inc. | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
-
2019
- 2019-02-22 EP EP19711736.9A patent/EP3755696B1/en active Active
- 2019-02-22 WO PCT/US2019/019129 patent/WO2019165192A1/en not_active Ceased
- 2019-02-22 KR KR1020207027174A patent/KR102861944B1/ko active Active
- 2019-02-22 AU AU2019224075A patent/AU2019224075A1/en not_active Abandoned
- 2019-02-22 PE PE2020001271A patent/PE20211447A1/es unknown
- 2019-02-22 MX MX2020008852A patent/MX2020008852A/es unknown
- 2019-02-22 ES ES19711736T patent/ES2945558T3/es active Active
- 2019-02-22 US US16/283,366 patent/US10934297B2/en active Active
- 2019-02-22 CA CA3091913A patent/CA3091913A1/en active Pending
- 2019-02-22 CN CN201980027314.1A patent/CN112020501A/zh active Pending
- 2019-02-22 BR BR112020017087-9A patent/BR112020017087A2/pt not_active IP Right Cessation
- 2019-02-22 MA MA051908A patent/MA51908A/fr unknown
- 2019-02-22 JP JP2020544501A patent/JP7369132B2/ja active Active
- 2019-02-22 SG SG11202008029UA patent/SG11202008029UA/en unknown
- 2019-02-22 EA EA202092002A patent/EA202092002A1/ru unknown
-
2020
- 2020-08-19 IL IL276814A patent/IL276814A/en unknown
- 2020-08-20 PH PH12020551300A patent/PH12020551300A1/en unknown
- 2020-08-24 CL CL2020002177A patent/CL2020002177A1/es unknown
- 2020-12-30 US US17/138,098 patent/US11713320B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10934297B2 (en) | 2021-03-02 |
| PE20211447A1 (es) | 2021-08-05 |
| KR102861944B1 (ko) | 2025-09-26 |
| BR112020017087A2 (pt) | 2020-12-22 |
| ES2945558T3 (es) | 2023-07-04 |
| EP3755696B1 (en) | 2023-04-05 |
| JP7369132B2 (ja) | 2023-10-25 |
| IL276814A (en) | 2020-10-29 |
| SG11202008029UA (en) | 2020-09-29 |
| CA3091913A1 (en) | 2019-08-29 |
| US20220402921A1 (en) | 2022-12-22 |
| KR20200126393A (ko) | 2020-11-06 |
| PH12020551300A1 (en) | 2021-10-25 |
| CL2020002177A1 (es) | 2021-01-08 |
| US11713320B2 (en) | 2023-08-01 |
| JP2021516674A (ja) | 2021-07-08 |
| MX2020008852A (es) | 2020-10-14 |
| CN112020501A (zh) | 2020-12-01 |
| AU2019224075A1 (en) | 2020-09-10 |
| US20190263821A1 (en) | 2019-08-29 |
| WO2019165192A1 (en) | 2019-08-29 |
| MA51908A (fr) | 2021-06-02 |
| EP3755696A1 (en) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092002A1 (ru) | 5-гетероарилзамещенные индазол-3-карбоксамиды и их получение и применение | |
| PH12018502259A1 (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| PH12016501835A1 (en) | 5-substituted indazole -3- carboxamides and preparation and use thereof | |
| MX385859B (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas. | |
| EA202091267A1 (ru) | 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47 | |
| MX2015008860A (es) | Inhibidores de 3-(benzoimidazol-2-il)-indazol de la senda de señalizacion de wnt y usos terapeuticos de los mismos. | |
| NZ727358A (en) | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof | |
| EA201891988A1 (ru) | Ингибиторы mcl-1 на основе замещенных индолов | |
| EA201891583A1 (ru) | Модуляторы экто-5'-нуклеотидазы и их применение | |
| MY184882A (en) | Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathyway inhibitors | |
| EA201990187A1 (ru) | Антипролиферационные средства на основе пиримидина | |
| EA201891974A1 (ru) | Ингибиторы связывания белка wdr5 с белками | |
| EA201491592A1 (ru) | Соединения индолов и индазолов, активирующие ampk | |
| MX389724B (es) | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| EA201691141A1 (ru) | Соединения против ccr6 | |
| CR20210442A (es) | ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y (Divisional Exp. 2020-0214) | |
| EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| EA202092305A1 (ru) | Соединения в качестве модуляторов сигнализации tlr2 | |
| EA202091524A1 (ru) | Ингибиторы рецептора, активируемого протеазой 2 | |
| EA201690400A1 (ru) | Замещенные имидазолы, используемые в качестве блокаторов кальциевых каналов n-типа | |
| EA201892113A1 (ru) | Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов | |
| EA201991735A1 (ru) | Азолопиримидины для лечения раковых заболеваний | |
| EA202092082A1 (ru) | Соединения аминопиразиндиола как ингибиторы pi3k- |